Anvisa Approves Mounjaro for Obesity: Hope and High Costs in Brazil

Brazil's Anvisa Approves Mounjaro for Obesity Treatment Brazil's National Health Surveillance Agency (Anvisa) has expanded the approved uses of the drug Mounjaro to include obesity treatment. This follows its previous approval for type 2 diabetes. Mounjaro, which works similarly to Ozempic and Wegovy, is now an option for Brazilians battling obesity, provided they have at least one comorbidity such as high blood pressure or cholesterol. "Mounjaro is a weekly injection that acts similarly to other pens, mimicking hormones that promote satiety and control appetite," explains Carol Simões, a presenter for G1 news. The drug's approval is expected to significantly impact obesity treatment in Brazil. However, the cost is a barrier for many. A box of four pens can range from R$1400 to R$2300, depending on the dosage and whether the patient participates in the manufacturer's program. A prescription is also required. Despite its potential, Anvisa emphasizes that Mounjaro should be used under the guidance of a healthcare professional and accompanied by lifestyle changes for optimal effectiveness. This approval marks a significant step forward in obesity treatment options in Brazil, but access remains a challenge due to the high cost and prescription requirements.